NLRP3 inflammasome polymorphism and macrovascular complications in type 2 diabetes patients

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Klen, Jasna ^a   Goričar, Katja ^b   Janež, Andrej ^c   Dolžan, Vita ^b  

^a Dialysis Department   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CRYOPYRIN; GLUCOSE; INFLAMMASOME; CARRIER PROTEIN; GLUCOSE BLOOD LEVEL; LIPID; NLRP3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETIC PATIENT; DISEASE DURATION; END STAGE RENAL DISEASE; FEMALE; GENETIC RISK; GENOTYPE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RETINOPATHY; ADOLESCENT; ANALYSIS; BLOOD; CHEMISTRY; COMPLICATION; DIABETES MELLITUS; GENETIC POLYMORPHISM; GENETICS; INFLAMMATION; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; VASCULAR DISEASE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD PRESSURE; CARRIER PROTEINS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; INFLAMMASOMES; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR DISEASES;

EID: 84939152473     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/616747     Document Type: Article

References (38)

1. R. Turner, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group," The Lancet, vol. 352, no. 9131, pp. 837-853, 1998.
2. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, "10-Year follow-up of intensive glucose control in type 2 diabetes,"The New England Journal of Medicine, vol. 359, no. 15, pp. 1577-1589, 2008.
3. H. Kolb and T. Mandrup-Poulsen, "An immune origin of type 2 diabetes?" Diabetologia, vol. 48, no. 6, pp. 1038-1050, 2005.
4. A. Pradhan, "Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders," Nutrition Reviews, vol. 65, no. 12, part 2, pp. S152-S156, 2007.
5. N. Esser, S. Legrand -Poels, J. Piette, A. J. Scheen, and N. Paquot, "Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes,"Diabetes Research and Clinical Practice, vol. 105, no. 2, pp. 141-150, 2014.
6. B. C. Cumbie and K. L. Hermayer, "Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications," Vascular Health and Risk Management, vol. 3, no. 6, pp. 823-832, 2007.
7. L. Gnudi, "Cellular and molecular mechanisms of diabetic glomerulopathy," Nephrology Dialysis Transplantation, vol. 27, no. 7, pp. 2642-2649, 2012.
8. M. Y. Donath, "Targeting inflammation in the treatment of type diabetes: time to start," Nature Reviews Drug Discovery, vol. 13, no. 6, pp. 465-476, 2014.
9. E. Benetti, F. Chiazza, N. S. A. Patel, and M. Collino, "The NLRP3 inflammasome as a novel player of the intercellular crosstalk in metabolic disorders," Mediators of Inflammation, vol. 2013, Article ID 678627, 9 pages, 2013.
10. D. R. Mason, P. L. Beck, and D. A. Muruve, "Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases," Journal of Innate Immunity, vol. 4, no. 1, pp. 16-30, 2011.
11. K. Schroder and J. Tschopp, "Theinflammasomes," Cell, vol. 140, no. 6, pp. 821-832, 2010.
12. J. M. Fernández-Real and J. C. Pickup, "Innate immunity, insulin resistance and type 2 diabetes," Diabetologia, vol. 55, no. 2, pp. 273-278, 2012.
13. Y. Zheng, D. Zhang, L. Zhang, M. Fu, Y. Zeng, and R. Russell, "Variants of NLRP3 gene are associated with insulin resistance inChineseHan population with type-2 diabetes," Gene, vol. 530, no. 1, pp. 151-154, 2013.
14. J. Chmelar, K.-J. Chung, and T. Chavakis, "The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance,"Thrombosis and Haemostasis, vol. 109, no. 3, pp. 399-406, 2013.
15. D. Verma, E. Särndahl, H. Andersson, et al., "The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-18 production," PLoS ONE, vol. 7, no. 4, Article ID e34977, 2012.
16. B. Sahdo, K. Fransén, B. A. Idosa, et al., "Cytokine profile in a cohort of healthy blood donors carrying polymorphisms in genes encoding the NLRP3 inflammasome," PLoS ONE, vol. 8, no. 10, Article ID e75457, 2013.
17. G. P. Varghese, K. Fransen, A. Hurtig-Wennlof, T. Bengtsson, J. H. Jansson, and A. Sirsjo, "Q705K variant in NLRP3 gene confers protection against myocardial infarction in female individuals," Biomedical Reports, vol. 1, no. 6, pp. 879-882, 2013.
18. A. Dehghan, Q. Yang, A. Peters, et al., "Association of novel genetic loci with circulating fibrinogen levels a genome-wide association study in 6 population-based cohorts," Circulation: Cardiovascular Genetics, vol. 2, no. 2, pp. 125-133, 2009.
19. A. Dehghan, J. Dupuis, M. Barbalic, et al., "Meta-analysis of genome-wide association studies in <80 000 subjects identifies multiple loci for C-reactive protein levels," Circulation, vol. 123, no. 7, pp. 731-738, 2011.
20. J. Klen, V. Dolžan, and A. Janež, "CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients," European Journal of Clinical Pharmacology, vol. 70, no. 4, pp. 421-428, 2014.
21. M. Takahashi, "NLRP3 inflammasome as a novel player in myocardial infarction," International Heart Journal, vol. 55, no. 2, pp. 101-105, 2014.
22. C. L. Wassel, L. A. Lange, B. J. Keating, et al., "Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the Cand idate Gene Association Resource (CARe)," Blood, vol. 117, no. 1, pp. 268-275, 2011.
23. M. Kawaguchi, M. Takahashi, T. Hata, et al., "Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury," Circulation, vol. 123, no. 6, pp. 594-604, 2011.
24. Y. Li, S. Xu, B. Jiang, R. A. Cohen, and M. Zang, "Activation of sterol regulatory element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in diabetic pigs," PLoS ONE, vol. 8, no. 6, Article ID e67532, 2013.
25. C. M. Turner, N. Arulkumaran, M. Singer, R. J. Unwin, and F. W. Tam, "Is the inflammasome a potential therapeutic target in renal disease?" BMC Nephrology, vol. 15, no. 1, article 21, 2014.
26. T. Fujita, N. Ogihara, Y. Kamura, et al., "Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications," Acta Diabetologica, vol. 49, no. 2, pp. 111-117, 2012.
27. M. Carlström, A.-K. Ekman, S. Petersson, P. Söderkvist, and C. Enerbäck, "Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility," Experimental Dermatology, vol. 21, no. 12, pp. 932-937, 2012.
28. R. J. Mathews, J. I. Robinson, M. Battellino, et al., "Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment," Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 1202-1210, 2014.
29. M. Ben Hamad, F. Cornelis, S. Marzouk, et al., "Association study of CARD8 (p. C10X) and NLRP3 (p. Q705K) variants with rheumatoid arthritis in French and Tunisian populations," International Journal of Immunogenetics, vol. 39, no. 2, pp. 131-136, 2012.
30. C. Yang, S. Huang, and B. Chiang, "Association of NLRP3 and CARD8 genetic polymorphisms with juvenile idiopathic arthritis in a Taiwanese population," Scand inavian Journal of Rheumatology, vol. 43, no. 2, pp. 146-152, 2014.
31. Y. Bai, S. Nie, G. Jiang, et al., "Regulation of CARD8 expression by ANRIL and association of CARD8 single nucleotide polymorphism rs2043211 (p. C10X)with ischemic stroke," Stroke, vol. 45, no. 2, pp. 383-388, 2014.
32. B. Vidan-Jeras, B. Jurca, V. Dolžan, M. Jeras, K. Breskvar, and M. Bohinjec, "Slovenian caucasian normal," in HLA 1998, P. I. Terasaki and D. W. Gjerston, Eds., pp. 180-181, American Society for Histocompatibility and Immunogenetics, Lenexa, Kan, USA, 1998.
33. G. Parati, G. Bilo, and J. E. Ochoa, "Benefits of tight blood pressure control in diabetic patients with hypertension: importance of early and sustained implementation of effective treatment strategies," Diabetes Care, vol. 34, supplement 2, pp. S297-S303, 2011.
34. R. Scarpioni, M. Ricardi, V. Albertazzi, and L. Melfa, "Treatment of dyslipidemia in chronic kidney disease: effectiveness and safety of statins," World Journal of Nephrology, vol. 1, no. 6, pp. 184-194, 2012.
35. A. González-Chávez, S. Elizondo-Argueta, G. Gutiérrez-Reyes, and J. I. León-Pedroza, "Pathophysiological implications between chronic inflammation and the development of diabetes and obesity," Cirugia y Cirujanos, vol. 79, no. 2, pp. 209-216, 2011.
36. K. M. Sumpter, S. Adhikari, E. K. Grishman, and P. C. White, "Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes," Pediatric Diabetes, vol. 12, no. 7, pp. 656-667, 2011.
37. K. Alexandraki, C. Piperi, C. Kalofoutis, J. Singh, A. Alaveras, and A. Kalofoutis, "Inflammatory process in type 2 diabetes: the role of cytokines," Annals of the New York Academy of Sciences, vol. 1084, pp. 89-117, 2006.
38. B. S. Nikolajczyk, M. Jagannathan-Bogdan, H. Shin, and R. Gyurko, "State of the union between metabolism and the immune system in type 2 diabetes," Genes and Immunity, vol. 12, no. 4, pp. 239-250, 2011.